High incidence of treatment‐induced and vaccine‐escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B–infected patients
Karine Lacombe, Anders Boyd, Fabien Lavocat, Christian Pichoud, Joel Gozlan, Patrick Miailhes, Caroline Lascoux‐Combe, Guy Vernet, Pierre‐Marie Girard, Fabien Zoulim – 6 March 2013 – Anti–hepatitis B virus (HBV) nucleos(t)ides analogs (NA) exert selective pressures on polymerase (pol) and surface (S) genes, inducing treatment resistance and increasing the risk of vaccine escape mutants. The rate of emergence for these mutations is largely unknown in patients coinfected with human immunodeficiency virus (HIV) and HBV undergoing dual‐active therapy.